What is NDC 71390-125?

71390-125 is the product NDC for Barhemsys (amisulpride), Amisulpride 2.5 mg/mL injection, solution, listed with the FDA by Acacia Pharma Ltd. It has 2 package NDCs, shown above in 10- and 11-digit form.

Acacia Pharma Ltd, NDC labeler code 71390. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Barhemsys?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Barhemsys NDC 71390-125 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)71390-125Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71390-0125Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71390-125-20	71390012520	10 CARTON in 1 PACKAGE (71390-125-20) / 1 VIAL, SINGLE-DOSE in 1 CARTON (71390-125-21) / 2 mL in 1 VIAL, SINGLE-DOSEMarketed from Feb 27, 2020
71390-125-50	71390012550	10 CARTON in 1 PACKAGE (71390-125-50) / 1 VIAL, SINGLE-DOSE in 1 CARTON (71390-125-51) / 4 mL in 1 VIAL, SINGLE-DOSEMarketed from Feb 27, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Barhemsys
Generic name (nonproprietary): amisulpride
Active ingredients: Amisulpride — 2.5 mg/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Acacia Pharma LtdNDC labeler code 71390
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 209510
Marketing start: Feb 27, 2020
Marketing end: Nov 30, 2030
Other FDA classes: Dopamine D2 Antagonists (Mechanism)
Identifiers: Product ID 71390-125_65f9d1f3-9e6a-48bd-8ae3-fee41402cd36SPL ID 65f9d1f3-9e6a-48bd-8ae3-fee41402cd36SPL set ID ab23bc6e-b6a8-165f-e053-2a95a90ab144RxCUI 2284232, 2284237, 2467148, 2467149UNII 8110R61I4U
Pharmacologic class: Dopamine-2 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N471390012520 followed by a unit qualifier and the quantity

Package 71390-0125-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 17, 2026.

Indications (excerpt from the label)

BARHEMSYS ® is indicated in adults for: prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. BARHEMSYS is a dopamine-2 (D 2 ) antagonist indicated in adults for: Prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. ( 1 ) Treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 71390-125

What is NDC 71390-125?: 71390-125 is the product NDC for Barhemsys (amisulpride), Amisulpride 2.5 mg/mL injection, solution, listed with the FDA by Acacia Pharma Ltd. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Barhemsys (Amisulpride).
What is the active ingredient?: Amisulpride.
Who is the labeler?: Acacia Pharma Ltd, NDC labeler code 71390. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Barhemsys?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Barhemsys (Amisulpride) NDC 71390-125